5956821
Last Update Posted: 2025-03-04
Recruiting
All Genders accepted | 1 Years-21 Years |
20 Estimated Participants | No Expanded Access |
Interventional Study | Accepts healthy volunteers |
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients < 22 years of age.
Eligibility
Relevant conditions:
Glioblastoma Multiforme
Anaplastic Astrocytoma
Fibrillary Astrocytomas
Oligodendroglioma
Diffuse Intrinsic Brainstem Glioma
Diffuse Intrinsic Pontine Glioma
DIPG Brain Tumor
H3 K27M
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Contact Information
Overall Contact
Heather McCrea, MD
hmccrea@med.miami.edu
305-585-3627
Data sourced from ClinicalTrials.gov